Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 15/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | HTR2B | P41595 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | GALR3 | O60755 | 1/20 | 0.58 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622483 | 0.94 | HCRTR2 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL3622904 | 0.90 | HCRTR1 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL3624130 | 0.90 | HCRTR1 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL3622216 | 0.89 | HCRTR1 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL3623216 | 0.88 | HCRTR1 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL3617294 | 0.87 | HCRTR1 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL2278091 | 0.87 | HCRTR2 (0.77) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL2312870 | 0.87 | HCRTR2 (0.77) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL3625065 | 0.86 | HCRTR1 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL2279797 | 0.86 | HCRTR2 (0.76) | HCRTR2HCRTR1HTR1AOPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | claimed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | claimed |
| EP-2131654-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| WO-2008108991-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| EP-2131654-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008108991-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108991-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885HTR1A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.